AU2007325123B2 - AZA-indolyl compounds and methods of use - Google Patents

AZA-indolyl compounds and methods of use Download PDF

Info

Publication number
AU2007325123B2
AU2007325123B2 AU2007325123A AU2007325123A AU2007325123B2 AU 2007325123 B2 AU2007325123 B2 AU 2007325123B2 AU 2007325123 A AU2007325123 A AU 2007325123A AU 2007325123 A AU2007325123 A AU 2007325123A AU 2007325123 B2 AU2007325123 B2 AU 2007325123B2
Authority
AU
Australia
Prior art keywords
alkyl
mmol
nhc
cr19r20
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007325123A
Other languages
English (en)
Other versions
AU2007325123A1 (en
Inventor
Liang Bao
Hazel Joan Dyke
Simon Charles Goodacre
Wendy Lee
John Gary Montana
Stephen Price
Mark S. Stanley
Karen Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2007325123A1 publication Critical patent/AU2007325123A1/en
Application granted granted Critical
Publication of AU2007325123B2 publication Critical patent/AU2007325123B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2007325123A 2006-11-30 2007-11-29 AZA-indolyl compounds and methods of use Ceased AU2007325123B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US86805506P 2006-11-30 2006-11-30
US60/868,055 2006-11-30
US91762007P 2007-05-11 2007-05-11
US60/917,620 2007-05-11
US94474307P 2007-06-18 2007-06-18
US60/944,743 2007-06-18
PCT/US2007/085962 WO2008067481A1 (en) 2006-11-30 2007-11-29 Aza-indolyl compounds and methods of use

Publications (2)

Publication Number Publication Date
AU2007325123A1 AU2007325123A1 (en) 2008-06-05
AU2007325123B2 true AU2007325123B2 (en) 2012-12-13

Family

ID=39169665

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007325123A Ceased AU2007325123B2 (en) 2006-11-30 2007-11-29 AZA-indolyl compounds and methods of use

Country Status (14)

Country Link
US (1) US7855216B2 (OSRAM)
EP (1) EP2099796B1 (OSRAM)
JP (1) JP5211063B2 (OSRAM)
AR (1) AR064031A1 (OSRAM)
AT (1) ATE511509T1 (OSRAM)
AU (1) AU2007325123B2 (OSRAM)
CA (1) CA2672327A1 (OSRAM)
CL (1) CL2007003444A1 (OSRAM)
DK (1) DK2099796T3 (OSRAM)
PE (1) PE20081354A1 (OSRAM)
PL (1) PL2099796T3 (OSRAM)
PT (1) PT2099796E (OSRAM)
TW (1) TW200829586A (OSRAM)
WO (1) WO2008067481A1 (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526267A (ja) * 2008-07-03 2011-10-06 バイエル ファーマ アクチエンゲゼルシャフト 化合物および放射性医薬品の製造方法
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
CA2789696C (en) 2010-02-25 2017-11-07 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
SG10201505951VA (en) * 2010-07-30 2015-08-28 Oncotherapy Science Inc Quinoline derivatives and melk inhibitors containing the same
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
UY34893A (es) 2012-07-10 2014-02-28 Takeda Pharmaceutical Derivados de azaindol
EP2916859B1 (en) 2012-11-02 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
UA111925C2 (uk) 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
WO2017180581A1 (en) 2016-04-15 2017-10-19 Genentech, Inc. Diagnostic and therapeutic methods for cancer
US11161845B2 (en) 2017-05-19 2021-11-02 Nflection Therapeutics, Inc. Pyrrolopyridine-aniline compounds for treatment of dermal disorders
ES2913213T3 (es) 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
KR102811888B1 (ko) 2017-09-08 2025-05-27 에프. 호프만-라 로슈 아게 암의 진단 및 치료 방법
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
WO2020106305A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Thienyl-aniline compounds for treatment of dermal disorders
CA3120337A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
EP3883552B1 (en) 2018-11-20 2025-04-09 NFlection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
MX2024006058A (es) 2021-11-23 2024-07-10 Nflection Therapeutics Inc Formulaciones de compuestos de pirrolopiridina-anilina.
EP4469456A4 (en) * 2022-01-28 2025-12-31 Insilico Medicine Ip Ltd Ectunocleotide pyrophosphatase-phosphodiesterase 1 (ENPP1) inhibitors and their uses
CN119013276A (zh) * 2022-03-04 2024-11-22 三进制药株式会社 新型杂环化合物和包含该化合物的药物组合物
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer
WO2025026383A1 (en) * 2023-08-02 2025-02-06 Insilico Medicine Ip Limited Crytsalline forms of ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
WO2025100940A1 (ko) * 2023-11-07 2025-05-15 보로노이 주식회사 헤테로아릴 유도체 화합물 및 이의 용도
WO2026019990A1 (en) 2024-07-18 2026-01-22 Genentech, Inc. Methods of treating cancer with anti-ccr8/anti-cd3 bispecific antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002051A1 (en) * 2004-06-15 2006-01-05 Schering Corporation Tricyclic compounds and their use as mglur1 antagonists
WO2006100095A1 (de) * 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte carbonsäureamide, verfahren zu ihrer herstellung und ihre verwendung als tnf-alpha-freisetzungsinhibitoren
WO2007070393A2 (en) * 2005-12-13 2007-06-21 Schering Corporation Mglur1 anatgonists as therapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
ATE361910T1 (de) 2002-04-23 2007-06-15 Aventis Pharma Inc 3-(pyridinyl-amino)-1h-indol-2-carbonsäure- verbindungen als inhibitoren der interleukin-4 genexpression
US6929411B2 (en) * 2003-09-03 2005-08-16 Hewlett-Packard Development Company, L.P. Selectable control of raster image processor
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
AR070127A1 (es) * 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002051A1 (en) * 2004-06-15 2006-01-05 Schering Corporation Tricyclic compounds and their use as mglur1 antagonists
WO2006100095A1 (de) * 2005-03-24 2006-09-28 Curacyte Discovery Gmbh Substituierte carbonsäureamide, verfahren zu ihrer herstellung und ihre verwendung als tnf-alpha-freisetzungsinhibitoren
WO2007070393A2 (en) * 2005-12-13 2007-06-21 Schering Corporation Mglur1 anatgonists as therapeutic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KANTH, ET AL. Heterocycles, (2005), 65(6): 1415-1423 *

Also Published As

Publication number Publication date
PT2099796E (pt) 2011-09-06
EP2099796A1 (en) 2009-09-16
CA2672327A1 (en) 2008-06-05
EP2099796B1 (en) 2011-06-01
DK2099796T3 (da) 2011-09-05
ATE511509T1 (de) 2011-06-15
WO2008067481A1 (en) 2008-06-05
TW200829586A (en) 2008-07-16
PE20081354A1 (es) 2008-11-14
CL2007003444A1 (es) 2008-06-27
US7855216B2 (en) 2010-12-21
PL2099796T3 (pl) 2011-10-31
AR064031A1 (es) 2009-03-04
HK1135099A1 (en) 2010-05-28
JP5211063B2 (ja) 2013-06-12
JP2010511626A (ja) 2010-04-15
US20080242655A1 (en) 2008-10-02
AU2007325123A1 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
AU2007325123B2 (en) AZA-indolyl compounds and methods of use
CA2706571C (en) 5-anilinoimidazopyridines and methods of use
AU2007286808B2 (en) Aza-benzofuranyl compounds and methods of use
EP2069359B1 (en) Aza-benzothiophenyl compounds and methods of use
AU2009266956B2 (en) Bicyclic heterocycles as MEK kinase inhibitors
CN101583616B (zh) 氮杂苯并噻吩基化合物及使用方法
ES2366932T3 (es) Compuestos de aza-indolilo y métodos de utilización.
HK1135099B (en) Aza-indolyl compounds and methods of use
HK1147254B (en) 5-anilinoimidazopyridines and methods of use

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ AZA-INDOLYL COMPOUNDS AND METHODS OF USE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired